Navigation Links
Onyx Pharmaceuticals Announces Third Quarter 2008 Financial Results Teleconference and Webcast
Date:10/29/2008

EMERYVILLE, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will webcast a teleconference with management to discuss third quarter 2008 financial results and provide a general business overview on Thursday, November 06, 2008, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Financial results for the third quarter ended September 30, 2008 will be released earlier that day.
Interested parties may access a live webcast of the presentation on our website at: http://www.onyx-pharm.com/wt/page/event_calendar or by dialing 847-413-3235 and using the passcode 22936749. A replay of the presentation will be available on the Onyx website or by dialing 630-652-3044 and using the passcode 22936749 approximately one hour after the teleconference concludes. The replay will be available through December 06, 2008.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treated(TM). The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R), a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer, and other cancers. For more information about Onyx, visit the company's website at http://www.onyx-pharm.com.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. PUR Water Filtration Systems Can Remove Pharmaceuticals Identified in U.S. Tap Water - More Than 99 Percent for PUR Faucet Filters and More Than 96 Percent for PUR Pitchers*
2. Morria Biopharmaceuticals Plc Announces Preliminary Results Regarding Inflammatory Markers From its Phase II Study in Allergic Rhinitis
3. Watson Pharmaceuticals Reports Third Quarter 2008 Results
4. Raptor Pharmaceuticals Corp. to Present at Two Upcoming Healthcare Conferences
5. Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Alexion Pharmaceuticals Chooses Blue Mountain Regulatory Asset Manager(R) for Best-in-class Calibration Management Integrated with SAP(R)
8. Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
9. CoLucid Pharmaceuticals Names Linda Hogan VP of Business Development
10. Anadys Pharmaceuticals to Present at Bio Investor Forum
11. Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... A ... Patch® significantly improves the reproducibility and accuracy of placing precordial electrodes with little ... , Over the last 60 years, studies have shown that single electrode misplacement ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... and many more tools allowing FCPX editors to create professional looking video in ... , Perfect Harmony contains a beautifully designed 3D environment for placing in ...
(Date:12/4/2016)... ... December 03, 2016 , ... Penrose Senior Care Auditors® ... area” Tuesday evening at the 26th Annual SMU Cox Dallas 100™ Awards Ceremony ... Caruth Institute for Entrepreneurship. Dallas 100™, co-founded by the Caruth Institute, honors the ...
(Date:12/4/2016)... Washington DC (PRWEB) , ... December 04, 2016 , ... ... Environmental, one of the most certified and experienced Indoor Air Quality Companies in VA, ... Assessment and Remediation Regulations. , The new mold law in the district ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Lori G. ... Traurig, LLP’s Atlanta office, will speak at the American Conference Institute’s 21st Drug ... Traurig is also a Lead Sponsor of the conference. , Cohen, who chairs the ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... TAIPEI, Taiwan , Dec. 5, 2016 /PRNewswire/ ... ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) in Complete Hematologic ... safety and tolerability profile of ropeginterferon alfa-2b versus HU ... the ongoing long-term follow-up trial CONTINUATION-PV to obtain European marketing ... to present this data to the FDA as it seeks ...
(Date:12/4/2016)...   Pairnomix, LLC, a genetic research company and ... the White House, today announced that findings from its first ... candidate therapies for a patient with epileptic encephalopathy caused by ... at the 70 th Annual Meeting of the ... , December 2-6, 2016.  Pairnomix, unique process involves ...
(Date:12/4/2016)... Dec. 3, 2016  Findings from a Novartis ... CTL019, an investigational chimeric antigen receptor T cell ... young adult patients with B-cell acute lymphoblastic leukemia ... session at the 58th American Society of Hematology ... p.m.). The global Phase II study found that ...
Breaking Medicine Technology: